Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Conditions:   Recurrent Fallopian Tube Clear Cell Adenocarcinoma;   Recurrent Ovarian Clear Cell Adenocarcinoma;   Recurrent Platinum-Resistant Fallopian Tube Carcinoma;   Recurrent Platinum-Resistant Ovarian Carcinoma;   Recurrent Platinum-Resistant Primary Peritoneal Carcinoma;   Recurrent Prima ry Peritoneal Clear Cell Adenocarcinoma Interventions:   Biological: Etigilimab;   Biological: Nivolumab Sponsor:   M.D. Anderson Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials